StartUPDATES: New developments with healthcare startups – MedCity News

Vector illustration - Startup

In response to the CDC’s release of clinical criteria to guide the evaluation of patients under investigation (PUI) for Wuhan coronavirus (2019-nCoV), updated its Upper Respiratory Infection (URI) SmartExamTM modules to include coronavirus screening. SmartExam will automatically escalate positive screenings for further evaluation as well as continue to screen for flu diligently as we fly through one of the most destructive flu seasons in recent history.

Despite the hysteria, co-founder and CEO Dr. Ray Costantini is telling people that while “Coronavirus is a pandemic threat that is making headlines….it’s important…not to get caught up in a panic. The real threat facing a greater number of Americans is still the flu – especially those who haven’t yet been vaccinated this year. We’re up to at least 8,200 flu deaths already this year. There’s still time to get that shot.”

GYANT has inked a deal with Cleveland Clinic which will see the health system deepen its relationship with the telemedicine startup. Cleveland Clinic will expand its use of the company’s software to communicate with patients after they are discharged. The system, called GYANT, is currently being used at 10 different Cleveland Clinic locations, and is being rolled out to its Women’s Health Institute to help new mothers after they leave the hospital.

The Cleveland Clinic first began working with GYANT in 2018, as one of the startup’s first customers. So far, GYANT said, the Cleveland Clinic has seen a 39 percent increase in patient contact rate.

“When we started to work with them, we were still thinking about whether seniors and older generations would adapt to this technology,” co-founder and CEO Pascal Zuta said.  Click here to read more.

READ  Digital Risks raises $10.4m Series A - UKTN

South San Francisco, California-based Mammoth Biosciences said Thursday that it had raised $45 million in a Series B funding round, which brings the total amount of funding the company has raised to date to more than $70 million. Decheng Capital led the financing, with participation from Mayfield, NFX, Verily and Brook Byers.

The company, which is developing a way to use gene-editing technology to detect disease,  will use the new funding  to support development of its CRISPR-based diagnostics and extend its research to include applications of the technology to include gene editing and therapeutics. Click here to read more.

Time is running out to apply to the Pitch Perfect competition at MedCity INVEST in Chicago April 21-22. If you are a startup in biopharma, diagnostics, medical device, digital health or health services, click here to apply.



Please enter your comment!
Please enter your name here